Immunophenotyping of blood and bone marrow cells as a way to search for differentiation syndrome risk factors in acute promyelocytic leukemia
Background. Differentiation syndrome (DS) is a potentially fatal complication of therapy for acute promyelocytic leukemia (APL) with an incidence of up to 48 %. To date, no reliable DS risk factors have been found, with the exception of leukocytosis at the APL onset.Aim. To determine the risk factor...
Saved in:
| Main Authors: | A. A. Semenova, I. V. Galtseva, V. V. Troitskaya, N. M. Kapranov, Yu. O. Davydova, K. A. Nikiforova, A. G. Loseva, A. A. Ermolaev, V. A. Surimova, S. M. Kulikov, E. N. Parovichnikova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2024-04-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/923 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Risk factors for a differentiation syndrome in patients with acute promyelocytic leukemia
by: A. A. Semenova, et al.
Published: (2023-09-01) -
Combination of arsenicum trioxide and all trans retinoic acid in the treatment of relapsed acute promyelocytic leukemia
by: A. N. Sokolov, et al.
Published: (2015-06-01) -
A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide
by: Uday Kulkarni, et al.
Published: (2020-04-01) -
Characteristics and Outcomes of Patients with Acute Promyelocytic Leukemia: A Single-center Experience
by: Sema Seçilmiş, et al.
Published: (2025-08-01) -
Fast pH‐Driven Solubilization Method of Realgar (As4S4) to Reduce the Toxicity of Arsenic [As(III)] for Medicinal Purposes
by: Bojana Lucic, et al.
Published: (2025-08-01)